Paresthesia Treatment Market to Witness Widespread Expansion During 2020-2027

 Paresthesia Treatment is a neurological condition in which impulsive or evoked abnormal sensations occur in the human body. In worst cases, the symptom can become chronic and life-time. Moreover, the existence of diseases like diabetes, arthritis, and cancer increases the possibility of this diseases. The global Paresthesia Treatment market is majorly influenced by increasing incidence of diabetes, cancer, and other chronic diseases, growing geriatric population, and changing lifestyle. Excess consumption of smoking and alcohol, the government initiatives for research & development, and lack of proper diet & exercise have fuelled the growth of the global market. However, strict regulatory approvals and long term drug approval time may hamper the market growth during the forecasted period.

The market is forecasted to demonstrate a steady growth by 2027, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2027.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/719 

The global Paresthesia Treatment market is segmented on the basis of types, treatments, and end users. On the basis of types, the market is segmented into acute paresthesia, chronic paresthesia. On the basis of treatments, the market is segmented into immunosuppressant, anticonvulsants, tropical creams, antivirals, and others. Immunosuppressant is further classified into prednisone, intravenous gamma globulin, and others. Topical creams are further classified into lidocaine, prilocaine, and others. On the basis of end users, the market is segmented into hospitals, clinics, diagnosis centers, and others.

Global Paresthesia Treatment Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Paresthesia Treatment appears to be highly competitive and fragmented. With well-established market in the Americas region major companies like Boston Scientific Corporation, Stimwave LLC, Nevro Corp, Cyberonics, Inc, EnteroMedics Inc, St. Jude Medical, LLC, Baxter, Stryker, and various others have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

The global Paresthesia Treatment treatments market is highly fragmented with the presence of many local players and international players. With the presence of large manufacturers, the local manufacturers are engaged in the cost reduction and innovation to ensure sustainability in the global market. Furthermore, some of the MNC’s are adopting various strategies such as partnerships and collaborations with other small and medium companies to expand their overall market share.

Medtronic, based in Dublin, Ireland, is one of the leading medical device manufacturer. Medtronic is one of the largest standalone medical technology development company across the globe. In January 2015, the company announced the acquisition of acquisition of Covidien plc. Under this agreement, Medtronic, Inc. and Covidien plc are now pooled under Medtronic plc.

This acquisition will enhance Medtronic’s scope past its array of spinal implants, insulin pumps, heart devices, and other devices into areas such as weight-loss surgery and laparoscopic treatment. The expansion will allow the company to better compete for business from hospitals, predominantly in the United States where changing healthcare organizations efforts and shrinking government reimbursement for medical procedures has kept burden on device pricing.

The acquisition will further leave Covidien shareholders owning about 30% of the combined company, is expected to result in at least USD 850 million of annual pre-tax cost collaborations by the end of fiscal year 2018.

Global Paresthesia Treatment Market - Regional Analysis

Global Paresthesia Treatment market is segmented on the basis of geographies or regions which mainly includes Americas, Europe, Asia Pacific, and Middle East & Africa. Americas is dominating the global market for Paresthesia Treatment with more than 40% share of the total market in 2016. The major factor for the growth of the market include due to high incidence of cancer and neurological disorders like Alzheimer’s, dementia. Increasing technology advancement and presence of major manufacturers furthermore influence the growth of market in Americas.  

Europe holds the second largest share of the global Paresthesia Treatment market. Asia Pacific is the fastest growing Paresthesia Treatment market across the globe. In Asia-Pacific there is wide range of opportunities for Paresthesia Treatment market due to the presence of developing countries, companies grabbing these opportunities and expanding their presence in the region. These rising development in the region is further influencing the growth of the market.   

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/paresthesia-treatment-market-719 

Research report covers the Protein Engineering Market Forecasts and Growth, 2020-2027

 Global Protein Engineering Market is expected to grow at a CAGR of approximately

6.2% During the Forecast Period of 2020 to 2027:
Market Scenario:
Proteins, the building blocks of the body, are large biomolecules made up of amino acids.
They perform various functions such as DNA replication, catalyzing metabolic reactions,
transporting molecules from one location to another, and responding to stimuli.
Furthermore, proteins also have a wide range of applications in the diagnosis of disease and
treatment development. Protein engineering involves designing and constructing new
proteins by modifying amino acid sequences to produce enzymes and desired properties and
the synthesis of proteins with a particular structure. This technology helps us to understand
the basics of how enzymes function and have evolved, and it is the key method of
improving enzyme properties for applications in pharmaceuticals, green chemistry, and
biofuels.
The major objective of protein engineering is to produce biological compounds which include
a synthetic peptide, storage protein, and synthetic drugs which will be superior to a normal
one and create an enzyme which is superior in its properties to produce high-value
chemicals in large quantities.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/691 

The global protein engineering market is driven by the increasing demand for new
technologies having their application in healthcare and by the growth in research and
development activities for improving health outcomes using novel technologies.
Furthermore, the emergence of trends in protein identification and tracking and the
increasing use of protein studies in research activities drive the growth of this market.
However, there are various factors that may hinder the growth of the market such as
expensive instruments used in protein engineering that require huge maintenance and lack
of trained personnel.

Key players

Agilent Technologies (U.S.), AB-Sciex (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Bruker Corp.
(U.S.), GE Healthcare (U.K.), Perkin Elmer (U.S.), Sigma-Aldrich Corp. (U.S.), Thermo
Fisher Scientific (U.S.), and Waters Corp. (U.S).

Market Segmentation

The global protein engineering market is segmented to the basis of type, method,
application, and end-users.
On the basis of type, the market is segmented into instrument, reagents, and services and
software.
On the basis of method, the market is segmented into rational protein design and directed
evolution.
On the basis of application, the market is segmented into food and detergent industries,
environment applications, medical applications, biopolymer production, and
nanobiotechnology.
On the basis of end-user, the market is segmented into academic research institutes,
pharmaceuticals and biotechnology companies, and contract engineering organizations.
Regional Analysis
Globally, protein engineering market consists of four regions, namely, Americas, Europe,
Asia Pacific, and the Middle East and Africa. North America is the largest market owing to
the concentration of major market players and increase in a number of biotechnology and
pharmaceutical companies. The U.S. is the largest market in North America followed by
Canada. In the U.S., extensive protein engineering technologies and methods and
availability of technologically-advanced devices and instruments for research also drive the
growth of the market.
Europe is the second largest market for protein engineering which is majorly driven by the
increasing demand for protein engineering methods and technologies and the overall growth
of research and development sector in major countries such as Germany, the U.K., and
France. Furthermore, the growth in funding for protein engineering and emphasis on drug
discovery are other factors expected to drive the growth of the market during the review
period.
Asia Pacific shows the fastest growth which is driven by the rising prevalence of lifestyle
diseases such as heart diseases, diabetes, obesity, and others and need for new
technologies with their application in healthcare.
The Middle East and Africa shows a steady but positive growth with an increase in the
demand for new drugs and devices for diagnosis and the treatment of diseases and
improvement in healthcare infrastructure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/protein-engineering-market-691 

Research report explores the Microfluidics Device Market for the forecast period, 2020-2027

 A microfluidic device is a well-accepted technology and has several applications. The technology allows integration of many medical tests on a single chip. It has become an essential technology for integration, industrialization, miniaturization and parallelization of various tests in the fields of diagnostics, drug development and biological research. The technology also helps in reducing the side effects and improving the efficacy of treatment. New microfluidic methods are used for evaluating drugs and manipulating cells for the treatment of diseases related to heart and cancer

Globally, the market for microfluidic devices is gaining significant importance due to growing R&D investment in life sciences, pharmaceuticals, increasing point of care testing demand and An increase in point of care testing, as an effective method for delivery of treatment, has also led to increase in the demand for microfluidic devices in the global market

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/684 

Some other factors driving the microfluidic devices market are rise in the commercial and analytical application of these devices and use of microfluidic products for miniaturization of chip.

Moreover some of the challenges faced by the market are adherence to stringent regulatory requirements to decelerate growth and geometrical and surface chemistry issues.

The use of microfluidic devices has been gaining importance into recent classification of research areas that target integration of laboratory protocols into miniaturized devices known as lab on chip.

This process includes many steps such as mixing, pre-treatment, reaction, separation, and pre-concentration. These processes help to reduce the cost and consume less reagent/sample, which is further helpful in various medical diagnosis with the help of blood drop. The miniaturization technique is expected to drive the microfluidic devices market, as this technique helps to reduce the overall cost of screening the compounds for cell biology problems by the pharmaceutical companies. Also the miniaturization technique helps in the reduction of analysis time and carry parallel assay in microfluidic devices, which is further expected to support the growth of this market.

Competitive Analysis:

Hoffmann-la Roche AG, Abbott laboratories, Siemens healthcare GMBH, Agilent technologies, Inc., Fluidigm corporation, bio-rad laboratories, ink, Cepheid, Raindance technologies, Inc., Dolomite centre, Micronit microfluidics, Johnson & Johnson, Becton, Dickinson and Company, These are some of the prominent players at the forefront of competition in the Global Microfluidic Devices Market.

Global Microfluidics Device Regional Analysis:

North America is the largest market for microfluidic devices, with factors such as growing old age population, increasing healthcare awareness, rising chronic and lifestyle diseases, technological developments for various home use applications and wider insurance infrastructure facilities driving the growth of microfluidic devices. With the rise in overall healthcare expenditure, the use of these devices has increased, since these devices provide accurate, reliable and quick results for early detection and prevention of diseases.

Due to its early introduction and wider applications in industries, use of microfluidic devices is high in North America as compared to other geographies. According to the European Federation of Pharmaceutical Industries and Associations, in 2014, the North American pharmaceutical market accounted for about 41.0% share of the global pharmaceutical market. High research and development expenditures in new drug lead to increase in the demand for various microfluidic devices for toxicity testing in the drug development process.

The European market for microfluidic devices is driven by increasing diagnostic requirements, due to rise in lifestyle associated diseases and increasing geriatric population. On the other hand, the increasing healthcare expenditure in the region has led to a shift in the focus of healthcare from hospitals to home, leading to increased use of microfluidic devices in the region.

According to the European Federation of Pharmaceutical Industries and Associations, R&D investment in Europe was about $40.2 billion, which lead to increased production of drugs in pipeline. The use of microfluidic devices is also expected to increase microreactors in drug synthesis and toxicity testing in drug development.

There are various regulatory issues related to microfluidic devices used for pharmaceutical research, point of care testing and clinical and veterinary diagnosis. The European Medical Devices Directives regulates the laws on performance and safety of the medical devices

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microfluidics-device-market-684 

Companion Diagnostics for Oncology Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Global Companion Diagnostics for Oncology Market is expected to register a CAGR of 22.57% during the forecast period and is expected to hit USD 5,064.17 Million by 2027.

A companion diagnostic is an in vitro diagnostic medical kit. Through this test, healthcare professionals can determine whether a particular therapeutic product is effective for the patient or possess any serious side effects or risks. The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, increasing global incidence of cancer, and increasing product approvals by major players. However, the lack of reimbursement in developing regions may hamper the market growth. The entry of market players in emerging economies creates growth opportunities for the companion diagnostics for the oncology market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422 

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. Similarly, in March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Furthermore, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane.

Segment Analysis

Global Companion Diagnostics for Oncology Market has been segmented based on products & services, technology, indication, and end user. The market, on the basis of products & services, has been segmented into assays, kits & reagents and software & services.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). The global market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others.

Regional Analysis

Global Companion Diagnostics for Oncology Market, based on region, is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is accounted for a major market share in 2019, whereas Asia-Pacific is projected to be the fastest-growing regional market during the forecast period.

In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Europe acquired the second-largest market share in 2019. The Europe market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activity to develop targeted drug therapy for a cancer patient, and the rising per capita income increasing the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific market is due to the growing number of cancer patients and rising presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the regional market. The Middle East and Africa accounted for the least market of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals, research laboratories, and increasing investment by healthcare companies in this region drives the growth of CDx in the Middle East & African countries.

Key Players

MRFR recognizes the following companies as the Key Players in the global Companion Diagnostics for Oncology Market— Agilent Technologies Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), BioMérieux SA (France), Foundation Medicine (US), Archer Dx (US), Qiagen (Germany), Thermo Fisher Scientific Inc. (US), and Amoy Dx (China) and Abbott Laboratories (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422 

Cardiopulmonary Resuscitation Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Global Cardiopulmonary Resuscitation Market is expected to register a CAGR of 10.50% during the forecast period and hit USD 300.6 Million by 2027.

Cardiopulmonary resuscitation (CPR) is an emergency and lifesaving technique. It consists of chest compression and artificial ventilation. CPR is performed to maintain the blood flow and oxygenation to the brain in case of cardiac arrest. CPR’s main function is to maintain the partial flow of oxygenated blood to the brain and heart. The main purpose is to delay tissue death to achieve successful resuscitation and protect the brain from permanent damage.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1348 

The increasing prevalence of heart and respiratory diseases, the rising geriatric population, and the rise in government initiatives are anticipated to drive the growth of the global cardiopulmonary resuscitation market. In April 2018, Stryker Launched Newest Version of LUCAS Chest Compression System in the US. The latest LUCAS 3.1 version allows professional users to tailor setup options for compression rate/depth, pause, alerts, timer, and ventilation features to meet local emergency care protocols. Moreover, in August 2019, ZOLL Medical Corporation announced acquisition of Cardiac Science. Cardiac Science Corporation is into the development, manufacturing, and marketing of automated external defibrillators (AEDs) and related parts, components, and accessories

Segment Analysis

Global Cardiopulmonary Resuscitation Market has been divided based on Product Type, Compressor Type, Application, and End User.

The market, based on Product Type, has been segregated into piston CPR devices, load-distributing band (LDB), active compression-decompression (ACD) devices and impedance threshold device, extracorporeal techniques and invasive perfusion devices, and others.

Based on compressor type, the Global Cardiopulmonary Resuscitation Market is segmented into manual CPR and automatic mechanical CPR.

The global market, on the basis of application, has been segmented into emergency departments, coronary & intensive care units, organ transplant facilities, air medevac units, and EMT rescue units.

On the basis of end-user, the market is bifurcated into the hospital & clinic, cardiac catheterization laboratories, organ transplant unit, and others.

Regional Analysis

Global Cardiopulmonary Resuscitation Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to hold the largest share of the global cardiopulmonary resuscitation market during the assessment period owing to the rise in the prevalence of lifestyle diseases and heart diseases. The Europe market is expected to register substantial growth in the market owing to the technological advancements, high disposable income, growing geriatric population, and favorable regulatory framework. Asia-Pacific is likely to hold the third-largest share of the global cardiopulmonary resuscitation market. The market in the Middle East & Africa is expected to witness gradual growth owing to the increasing number of heart & respiratory diseases coupled with rapidly developing healthcare infrastructure.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Cardiopulmonary Resuscitation Market— Stryker, Nihon Kohden Corporation, ZOLL Medical Corporation, Koninklijke Philips N.V., Vyaire Medical, Inc., General Electric Company, CPR Medical Devices, Inc., Michigan Instruments, Corpuls, SCHILLER, and Medtronic.

Key Findings of the Study

• Global Cardiopulmonary Resuscitation Market was valued at USD 3 Million in 2019 and is expected to register a CAGR of 10.50% during the assessment period.
• The Americas accounted for the largest share of the global market due to the rise in the prevalence of lifestyle diseases and heart diseases.
• Based on product type, the piston CPR devices segment is expected to register the highest CAGR of 11.57% during the forecast period.
• Based on compressor type, the automatic mechanical CPR segment accounted for the largest market share at a value of USD 101.6 Million in 2019.
• Based on application, the EMT rescue units segment is expected to register the highest CAGR of 12.71% during the forecast period.
• Based on end user, the hospitals and clinic segment accounted for the largest market share at a value of USD 136.1 Million in 2027.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cardiopulmonary-resuscitation-market-1348 

Smart Insulin Pens Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

 Market Research Future (MRFR) studied the global smart insulin pens market 2020 through the analysis period till 2027. By 2027, the global smart insulin pen market can expand at decent pace. On conclusion of the analysis period, the smart insulin market value can touch USD 72.97 Mn.

The escalating count of diabetics, surge in product launches and approvals, and expansion of geriatric populace can favor the smart insulin pen market in the forecast tenure. The alarming increase in diabetics across the globe due to surge in number of obese and ageing people, along with the prevailing culture of sedentary lifestyle, are creating the need for smart insulin pens. The intricate design of smart insulin pens allows refill, and Bluetooth and USB connectivity, which boost patient compliance. These causes are likely to promote the smart insulin pen market in the review period. The growing preference for homecare settings is expected to create lucrative scope for smart insulin pens manufacturers. However, high expense of insulin pens and challenges with their sales in underdeveloped nations can hinder the market growth. Investors are investing in strengthening the medical base of the market across these regions can counter the smart insulin pens market slow-down.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6789 

Segment Overview

The segment evaluation of the smart insulin pens market is based on distribution channel and product type. The product type-based segments of the smart insulin pens market are connecting device and smart pen. The smart pen segment can surge at considerable pace in the study period. The increase in sales of both smart pen and connecting device can earn high revenue for the market in the forecast tenure.  The smart pens segment can surge at 10.98% CAGR over the analysis period. The introduction of user-friendly design of smart insulin pens can prompt the market growth in the study period. As insulin pens brands focuses on innovations, the ingression of technical advances can prompt the market upsurge.

The distribution channel-based segments of the smart insulin market are hospitals or retail pharmacies, and online. The increase in number of hospital and retail pharmacies and them experiencing considerable surge in sales of smart insulin can favor the market. However, escalation of online sales of smart insulin pen as diabetic patients seek treatment and consultation on online platform can impact the market. MRFR study reveals that the hospital or retail pharmacies segment can value USD 47.97 Mn by 2027.

Regional Analysis

The smart insulin pen in the America is expected to rise at decent pace in the near future. The growth of the smart insulin pen market in the US is considerable due to rapid uptake of advanced medicines and diagnostic measures by several target patients. The presence of well-established healthcare industry and the large-scale manufacturing of medical device are causes that are expected to benefit North America market in the coming years. The emergence of new companies and active brand promotion strategies adopted by top-notch companies in the region can contribute to the expansion of the market in the coming years.

In APAC smart insulin pens market is likely to rise at the highest pace in the upcoming years. The expansion of the diagnostic health industry and increasing prominence of insulin pens can bolster the market expansion in India and other regions of APAC. The growing awareness about modern pen needles and active campaigns promoting smart insulin pens can benefit the market in the years to come. In Europe, the smart insulin market growth can be attributed to hike in investment made by international vendors to expand their global presence. The introduction of latest products for diabetes care and upscaling demand for green insulin pen can improve momentum of the market.

Competitive Landscape

Novo Nordisk A/S, Companion Medical, Digital Medics Pty Ltd., Emperra GmbH E-Health Technologies, Ypsomed Holding AG, Eli Lily and Company, and Amesco Co. Ltd., are some key players in the smart insulin market that are listed by MRFR. Adoption of strategic M&A for launching and promoting innovation can boost the competitive landscape of the smart insulin pen market in the study period. The smart insulin pens industry assessment by MRFR focuses on growth dynamics of the market that is impacted by businesses and manufacturers entering into relationships. Different firms are developing innovations in pump therapy and advanced glucose monitoring to boost patient medication compliance for growing cases of type 2 diabetes. The rise of the smart insulin pens and pumps market can also be attributed to product development by top-notch companies.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/smart-insulin-pens-market-6789 

Global EPharmacy Market Show Steady Growth: Study 2027

 The restrictions created by the COVID pandemic created a promising situation for the development of the ePharmacy market. Reports created by MRFR detail the developments in the industry that can be expected in the market through the forecast period. The market is predicted to achieve development with a CAGR of 12.5% by 2027.

The enhancement of distribution chains associated with pharmaceutical drugs is predicted to create impetus in the forecast period's ePharmacy market. The cost advantages are estimated to further promote the advancement of the ePharmacy market in the coming period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6615 

Segment Analysis

Global ePharmacy Market has been divided based on drug Type, Operating Platform, and Business Model.

The market, based on drug type, has been segregated into prescription drugs and over the counter (OTC) drugs.

Based on operating platform, the ePharmacy market has been divided into app and websites.

On the basis of business model, the ePharmacy market is segregated into the marketplace, pharmacy, and direct.

Regional Analysis

The global ePharmacy market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is likely to hold the largest share of the global ePharmacy market during the assessment period owing to the presence of a large number of ePharmacy in the region. Some of the renowned ePharmacy in the region include Walgreens Boots Alliance, Inc., Wal-Mart, Inc., CVS Health, PillPack, Inc., and others. According to a 2019 survey, 19% of health care providers in the U.S. offer a customer’s web-based prescription refill online program. It was also reported that several retail pharmacies have been offering mobile apps for an online prescription refill. A large number of companies such as Walgreens and CVS Pharmacy offer mobile apps to make prescription refill easy and convenient with a round to clock delivery. The ePharmacy market in Europe is expected to propel during the forecast period, owing to factors such as rising government initiatives, increasing awareness among customers regarding ePharmacy, and the convenience associated with the offered services. The fast growth of the Asia-Pacific region is due to rising investment for ePharmacy startups and the increasing per capita income along with government initiatives to enhance the quality of healthcare. China, India, and Australia have a lucrative market for ePharmacy due to the growing investment. The online pharmacy market in India attracted funding of USD 93 million by 2015. As a result, 60 online pharmacy start-ups emerged in 2017.

Key Players

MRFR recognizes the following companies as the Key Players in the Global ePharmacy Market— Walgreens Boots Alliance, Inc., Wal-Mart, Inc., CVS Health, Dr. Fox Pharmacy, DocMorris N.V., Rowlands Pharmacy, OptumRx, The Online Drugstore, Well Pharmacy, LloydsPharmacy and Others.

Key Findings of the Study

• The Global ePharmacy Market was valued at USD 62,587.0 Million and is expected to register a CAGR of 12.5% during the assessment period

• The Americas accounted for the largest share of the global market due to the increasing preference of customers to buy medications online and growth in the number of ePharmacy. These factors are driving the growth of the ePharmacy market in the region

• Based on the drug type, the prescription drugs segment accounted for the largest market share of 55.6% in 2019

• Based on the operating platform, the app segment accounted for the largest market share of 57.6% in 2019

• Based on the business model, the marketplace segment accounted for the largest market share with a value of USD 28,813.3 Million in 2019

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/epharmacy-market-6615